Abbott (NYSE: ABT) awards director 2,286 restricted stock units

Rhea-AI Filing Summary

Conroy Kevin T reported acquisition or exercise transactions in this Form 4 filing.

Abbott Laboratories director Kevin T. Conroy received a grant of 2,286 common shares in the form of restricted stock units. These units were awarded under the Abbott Laboratories 2026 Incentive Stock Program as compensation, not through an open-market purchase.

The award will be settled one-for-one in Abbott common shares upon the earlier of his separation from service, death, or a change in control as defined in the program. After this grant, Conroy directly holds 133,737 Abbott common shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Conroy Kevin T

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common shares without par value	2,286	$0.00	--

Holdings After Transaction: Common shares without par value — 133,737 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Restricted stock unit award: 2,286 shares Shares held after transaction: 133,737 shares Transaction price per share: $0.00

3 metrics

Restricted stock unit award 2,286 shares Grant under Abbott Laboratories 2026 Incentive Stock Program

Shares held after transaction 133,737 shares Director Kevin T. Conroy direct holdings after Form 4 grant

Transaction price per share $0.00 Compensation grant, not open-market purchase

Key Terms

restricted stock unit, Abbott Laboratories 2026 Incentive Stock Program, change in control

3 terms

restricted stock unit financial

"Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

Abbott Laboratories 2026 Incentive Stock Program financial

"award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program")"

change in control financial

"death, or the occurrence of a change in control (as defined by the Program)"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Conroy Kevin T

(Last) (First) (Middle)

100 ABBOTT PARK ROAD

(Street)

ABBOTT PARK ILLINOIS 60064

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ABBOTT LABORATORIES [ ABT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares without par value	04/24/2026		A		2,286(1)	A	$0	133,737	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted stock unit award granted under the Abbott Laboratories 2026 Incentive Stock Program (the "Program"). The award will be paid, on a one-to-one basis, in Abbott common shares on the earlier of the date of the director's separation from service, death, or the occurrence of a change in control (as defined by the Program).

	/s/ Kevin T. Conroy by Jessica H. Paik, Attorney-in-Fact	04/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Abbott Laboratories (ABT) director Kevin T. Conroy receive in this Form 4 filing?

Kevin T. Conroy received a grant of 2,286 restricted stock units tied to Abbott common shares. The award was issued as compensation under the Abbott Laboratories 2026 Incentive Stock Program, rather than bought on the open market, and increases his direct share holdings.

How many Abbott (ABT) shares does Kevin T. Conroy hold after this restricted stock award?

Following the grant, Kevin T. Conroy directly holds 133,737 Abbott common shares. This figure includes the impact of the 2,286-share restricted stock unit award reported in the Form 4, reflecting his updated direct ownership position in Abbott Laboratories.

How and when will Kevin T. Conroy’s Abbott (ABT) restricted stock units be paid out?

The restricted stock units will be paid in Abbott common shares on a one-to-one basis. Payment occurs at the earlier of Conroy’s separation from service, his death, or a change in control of Abbott as defined in the 2026 Incentive Stock Program.

Is the Abbott (ABT) Form 4 transaction an open-market purchase or a compensation grant?

The Form 4 transaction reflects a compensation grant, not an open-market purchase. Kevin T. Conroy received 2,286 restricted stock units at no stated purchase price under Abbott’s 2026 Incentive Stock Program, consistent with a director equity award structure.

What program governs Kevin T. Conroy’s restricted stock unit award from Abbott (ABT)?

The award is granted under the Abbott Laboratories 2026 Incentive Stock Program. This program sets the terms, including that the restricted stock units convert into Abbott common shares upon separation from service, death, or a defined change in control event.